Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function.

Katia Khoury,Ana Barac,Filipa Lynce,Xue Geng,Chau T. Dang,Anthony F. Yu,Karen Lisa Smith,Christopher Gallagher,Paula R. Pohlmann,Raquel Nunes,P. Herbolsheimer,R. Warren,M. Barbara Srichai,Mark Hofmeyer,Federico M. Asch,Ming Tony Tan,Claudine Isaacs,Sandra M. Swain

Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function.

2020

Katia Khoury
Ana Barac
Filipa Lynce
Xue Geng
Chau T. Dang
Anthony F. Yu
Karen Lisa Smith
Christopher Gallagher
Paula R. Pohlmann
Raquel Nunes
P. Herbolsheimer
R. Warren
M. Barbara Srichai
Mark Hofmeyer
Federico M. Asch
Ming Tony Tan
Claudine Isaacs
Sandra M. Swain

12069Background: HER2-targeted therapies are associated with cardiotoxicity, mostly asymptomatic and reversible. The impact of withholding these therapies on breast cancer outcomes is unknown. SAFE...

Keywords:

HER2 Positive Breast Cancer
Physical therapy
Internal medicine
Clinical trial
in patient
long term follow up
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations